GlassScriptPhysician profile
Youcef Sennour
NPI 1053369280
$1,561.97
in general payments reported to CMS, 2019-2025
21 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $51.11 · 2021: $112 · 2022: $97.26 · 2023: $31.37 · 2024: $59.32 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $226 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.58 |
| Education | $211.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $211.48 | 2025 | |
| Amarin Pharma, INC. | $178.65 | 2019-2022 | |
| Novo Nordisk INC | $158.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $155.94 | 2019-2024 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $146.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $141.05 | 2019-2020 | |
| Pfizer INC. | $122.93 | 2019-2021 | |
| Abbvie INC. | $89.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $62.88 | 2019-2021 | |
| Astellas Pharma US INC | $62.88 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $39.09 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.88 | 2019 | |
| Sumitomo Pharma America, INC. | $23.08 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $22.60 | 2025 | |
| Lilly USA, LLC | $20.87 | 2025 | Kisunla, Amyvid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $17.41 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.32 | 2022 | |
| Glaxosmithkline, LLC. | $16.26 | 2021 | |
| Medtronic Vascular, INC. | $15.61 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.78 | 2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youcef Sennour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.